Ramesh Jayaraman

1.2k citations

18 papers · 898 indexed · h-index 15

Co-authors: Kantharaj Ethirajulu Stefan Hart Anthony D. William Brian Dymock Jeanette M. Wood Veronica Novotny‐Diermayr Anders Poulsen Kee Chuan Goh
Topics: Cytokine Signaling Pathways and Interactions (7 papers)Myeloproliferative Neoplasms: Diagnosis and Treatment (4 papers)Chronic Lymphocytic Leukemia Research (3 papers)
Cited by: Genetics Hematology Oncology
Journals: Journal of Clinical Oncology The Journal of Immunology Scientific Reports
Partner nations: Singapore India United States

In The Last Decade

Ramesh Jayaraman

17 papers receiving 876 citations

Peers

Countries citing papers authored by Ramesh Jayaraman

Since Specialization

Citations

This map shows the geographic impact of Ramesh Jayaraman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ramesh Jayaraman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ramesh Jayaraman more than expected).

Fields of papers citing papers by Ramesh Jayaraman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ramesh Jayaraman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ramesh Jayaraman. The network helps show where Ramesh Jayaraman may publish in the future.

Co-authorship network of co-authors of Ramesh Jayaraman

This figure shows the co-authorship network connecting the top 25 collaborators of Ramesh Jayaraman. A scholar is included among the top collaborators of Ramesh Jayaraman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ramesh Jayaraman. Ramesh Jayaraman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

#	Work	Indexed citations
1	Neutropenic Rat Thigh Infection Model for Evaluation of the Pharmacokinetics/Pharmacodynamics of Anti-Infectives 2023 ·Microbiology Spectrum ·(unknown),(unknown),(unknown),(unknown),(unknown),Mahesh Nanjundappa,Ramesh Jayaraman	2
2	Effect of Blood Pressure Reduction on Intraocular Pressure and Ophthalmic Artery Blood Flow Velocity in Hypertension 2021 ·Journal of Ocular Pharmacology and Therapeutics ·(unknown),(unknown),(unknown),Ramesh Jayaraman,(unknown),(unknown)	0
3	Pharmacokinetics/Pharmacodynamics (PK/PD) of Ciprofloxacin in the Complicated Urinary Tract Infection (cUTI) Model in Diabetic Mice 2020 ·Current Drug Metabolism ·(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),Mahesh Nanjundappa,Ramesh Jayaraman	2
4	Linear Cyclodextrin Polymer Prodrugs as Novel Therapeutics for Niemann-Pick Type C1 Disorder 2018 ·Scientific Reports ·Aditya Kulkarni,Paola Caporali,(unknown),(unknown),Sandeep Goyal,Jessica Dragotto,Alberto Macone,Ramesh Jayaraman,Maria Teresa Fiorenza	27
5	Nitrothiophene carboxamides, a novel narrow spectrum antibacterial series: Mechanism of action and Efficacy 2018 ·Scientific Reports ·Shahul Hameed P,Nagakumar Bharatham,(unknown),Sreevalli Sharma,Radha Nandishaiah,(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),Ramesh Jayaraman,(unknown),Ramesh Subbiah,Vasanthi Ramachandran,V. Balasubramanian,Santanu Datta	20
6	Metabolism and Disposition of Pacritinib (SB1518), an Orally Active Janus Kinase 2 Inhibitor in Preclinical Species and Humans 2015 ·Drug Metabolism Letters ·Ramesh Jayaraman,Mohammed Khysar Pasha,Anthony P. Williams,Kee Chuan Goh,Kantharaj Ethirajulu	14
7	The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML 2012 ·Blood Cancer Journal ·Veronica Novotny‐Diermayr,Stefan Hart,(unknown),Albert Cheong,(unknown),Hannes Hentze,Mohammed Khysar Pasha,Ramesh Jayaraman,Kantharaj Ethirajulu,(unknown)	87
8	SB1578, a Novel Inhibitor of JAK2, FLT3, and c-Fms for the Treatment of Rheumatoid Arthritis 2012 ·The Journal of Immunology ·Babita Madan,Kee Chuan Goh,Stefan Hart,Anthony D. William,Ramesh Jayaraman,Kantharaj Ethirajulu,Brian Dymock,Jeanette M. Wood	27
9	Phase I Study of a Novel Oral Janus Kinase 2 Inhibitor, SB1518, in Patients With Relapsed Lymphoma: Evidence of Clinical and Biologic Activity in Multiple Lymphoma Subtypes 2012 ·Journal of Clinical Oncology ·Anas Younes,Jorge Romaguera,Michelle A. Fanale,Peter McLaughlin,Frederick Hagemeister,Amanda Copeland,Sattva S. Neelapu,Larry W. Kwak,Jatin J. Shah,Silvana de Castro Faria,Stefan Hart,Jeanette M. Wood,Ramesh Jayaraman,Kantharaj Ethirajulu,Joy Zhu	119
10	Preclinical Metabolism and Pharmacokinetics of SB1317 (TG02), a Potent CDK/JAK2/FLT3 Inhibitor 2012 ·Drug Metabolism Letters ·Mohammad Pasha,Ramesh Jayaraman,Venkatesh Pilla Reddy,Pauline Yeo,(unknown),Anthony P. Williams,Kee Chuan Goh,Kantharaj Ethirajulu	17
11	Discovery of the Macrocycle (9E)-15-(2-(Pyrrolidin-1-yl)ethoxy)-7,12,25-trioxa-19,21,24-triaza-tetracyclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2,4,9,14(26),15,17,20,22-nonaene (SB1578), a Potent Inhibitor of Janus Kinase 2/Fms-LikeTyrosine Kinase-3 (JAK2/FLT3) for the Treatment of Rheumatoid Arthritis 2012 ·Journal of Medicinal Chemistry ·Anthony D. William,(unknown),Anders Poulsen,Kee Chuan Goh,Babita Madan,Stefan Hart,(unknown),Haishan Wang,Harish Nagaraj,(unknown),(unknown),Eric T. Sun,Ramesh Jayaraman,(unknown),Kantharaj Ethirajulu,Jeanette M. Wood,Brian Dymock	36
12	Pharmacodynamic Evaluation of the Target Efficacy of SB939, an Oral HDAC Inhibitor with Selectivity for Tumor Tissue 2011 ·Molecular Cancer Therapeutics ·Veronica Novotny‐Diermayr,Nina Sausgruber,Yung Kiang Loh,Mohammad Pasha,Ramesh Jayaraman,Hannes Hentze,Wei Peng Yong,Boon-Cher Goh,(unknown),Kantharaj Ethirajulu,Joy Zhu,Jeanette M. Wood	19
13	TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties 2011 ·Leukemia ·(unknown),Veronica Novotny‐Diermayr,Stefan Hart,(unknown),Yung Kiang Loh,Albert Cheong,Yuxin Tan,(unknown),Ramesh Jayaraman,Anthony D. William,Eric T. Sun,Brian Dymock,Kiat Hoe Ong,Kantharaj Ethirajulu,Francis Burrows,J M Wood	105
14	SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies 2011 ·Leukemia ·Stefan Hart,(unknown),Veronica Novotny‐Diermayr,(unknown),Hannes Hentze,Yuxin Tan,Babita Madan,(unknown),Yung Kiang Loh,(unknown),Anthony D. William,(unknown),Anders Poulsen,Ramesh Jayaraman,Kiat Hoe Ong,Kantharaj Ethirajulu,Brian Dymock,(unknown)	152
15	Preclinical Metabolism and Disposition of SB939 (Pracinostat), an Orally Active Histone Deacetylase Inhibitor, and Prediction of Human Pharmacokinetics 2011 ·Drug Metabolism and Disposition ·Ramesh Jayaraman,Venkatesh Pilla Reddy,Mohammad Pasha,Haishan Wang,Kanda Sangthongpitag,Pauline Yeo,(unknown),Xiaofeng Wu,Xin Liu,(unknown),Lee Sun New,Kantharaj Ethirajulu	17
16	Discovery of Kinase Spectrum Selective Macrocycle (16E)-14-Methyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (SB1317/TG02), a Potent Inhibitor of Cyclin Dependent Kinases (CDKs), Janus Kinase 2 (JAK2), and Fms-like Tyrosine Kinase-3 (FLT3) for the Treatment of Cancer 2011 ·Journal of Medicinal Chemistry ·Anthony D. William,(unknown),Kee Chuan Goh,Stéphanie Blanchard,Anders Poulsen,(unknown),Harish Nagaraj,(unknown),Haishan Wang,Meredith Williams,Eric T. Sun,Changyong Hu,Ramesh Jayaraman,Mohammad Pasha,Kantharaj Ethirajulu,Jeanette M. Wood,Brian Dymock	78
17	Discovery of the Macrocycle 11-(2-Pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a Potent Janus Kinase 2/Fms-Like Tyrosine Kinase-3 (JAK2/FLT3) Inhibitor for the Treatment of Myelofibrosis and Lymphoma 2011 ·Journal of Medicinal Chemistry ·Anthony D. William,(unknown),Stéphanie Blanchard,Anders Poulsen,(unknown),Harish Nagaraj,(unknown),(unknown),Meredith Williams,Eric T. Sun,Kee Chuan Goh,(unknown),(unknown),Stefan Hart,Ramesh Jayaraman,Mohammad Pasha,Kantharaj Ethirajulu,Jeanette M. Wood,Brian Dymock	149
18	Glycine and alanine dehydrogenase activities are catalyzed by the same protein inMycobacterium smegmatis: upregulation of both activities under microaerophilic adaptation 2002 ·Canadian Journal of Microbiology ·Veeraraghavan Usha,Ramesh Jayaraman,Juan Carlos Toro,Sven Hoffner,(unknown)	27

About Ramesh Jayaraman

Ramesh Jayaraman is a scholar working on Genetics, Oncology and Hematology, having authored 18 papers that have together received 898 indexed citations. Recurring topics across this work include Cytokine Signaling Pathways and Interactions (7 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (4 papers) and Chronic Lymphocytic Leukemia Research (3 papers). The work is most often cited by research in Genetics (344 citations), Hematology (253 citations) and Oncology (352 citations). Ramesh Jayaraman has collaborated with scholars based in Singapore, India and United States. Frequent co-authors include Kantharaj Ethirajulu, Stefan Hart, Anthony D. William, Brian Dymock, Jeanette M. Wood, Veronica Novotny‐Diermayr, Anders Poulsen, Kee Chuan Goh, Eric T. Sun and Hannes Hentze. Their work appears in journals such as Journal of Clinical Oncology, The Journal of Immunology and Scientific Reports.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact